Fetal Genetic Variants Implicated in Spontaneous Preterm Birth Risk
|
By LabMedica International staff writers Posted on 03 Jul 2019 |

Image: The UltraClean BloodSpin DNA Isolation Kit is designed to isolate genomic and mitochondrial DNA from whole blood (fresh, frozen or stored at 4 °C), buffy coat or cultured cells (Photo courtesy of MO BIO Laboratories).
Preterm live births that take place before 37 completed weeks of gestation and even as early as 22–24 weeks are a global problem. Up to 11.1% (15 million babies) of all births worldwide occur prematurely, and approximately 45% to 50% of them are idiopathic or spontaneous.
Many pathways and cellular processes are reported to be associated with Spontaneous Preterm Birth (SPTB), including response to infection, regulation of inflammation, stress, and other immunologically mediated processes. A gene has been identified involved in axon guidance, neuronal migration, and inflammation, that appear to coincide with spontaneous preterm birth.
An international team of Finnish and American scientists led by the Oulu University Hospital (Oulu, Finland) studied a population that included 260 SPTB cases (139 male and 121 female infants) and 9,630 controls (4,055 males and 5,575 females). The cases were very preterm infants born between 25 and 30 weeks of gestation and were clinically defined as SPTB in 2005–2008. In the Finnish cohorts, SPTB was defined as birth occurring after spontaneous onset of labor at <36 completed weeks + 1 day of gestation.
Umbilical cord blood, umbilical cord tissue, or saliva was obtained from the study subjects. Commercial kits were used to extract genomic DNA from blood, or Puregene Blood Core Kit and cord tissue using Qiagen’s Gentra Puregene Tissue Kit. Genome-wide SNP genotyping was performed with the Infinium HumanCoreExome BeadChip. In total, 18 placental samples were analyzed by immunohistochemistry.
The team reported that after replication testing in hundreds more babies born particularly prematurely and thousands of control infants, they were left with a single nucleotide polymorphism (SNP) in the SLIT2 gene that was significantly associated with spontaneous preterm birth, as well as suggestive associations for SNPs in other axon guidance genes. The team's follow-up gene expression, localization, and functional experiments indicated that SLIT2 and ROBO1, which encodes SLIT2's receptor protein, are expressed at higher-than-usual levels in certain parts of the placenta for infants experiencing spontaneous preterm birth.
The most significant association with spontaneous birth involved a SNP called rs116461311 in SLIT2, prompting a series of immunohistochemistry, qRT-PCR, and gene silencing experiments on placental samples or cells that the scientists used to decode SLIT2-ROBO1 interactions and their consequences for birth timing. The authors concluded that based on the currently available evidence they propose that activation of SLIT2-ROBO1 expression and signaling in [placental] trophoblast cells contributes to inflammatory and immune activation, which in turn leads to early labor and preterm birth. The study was published on June 13, 2019, in the journal PLOS Genetics.
Related Links:
Oulu University Hospital
Many pathways and cellular processes are reported to be associated with Spontaneous Preterm Birth (SPTB), including response to infection, regulation of inflammation, stress, and other immunologically mediated processes. A gene has been identified involved in axon guidance, neuronal migration, and inflammation, that appear to coincide with spontaneous preterm birth.
An international team of Finnish and American scientists led by the Oulu University Hospital (Oulu, Finland) studied a population that included 260 SPTB cases (139 male and 121 female infants) and 9,630 controls (4,055 males and 5,575 females). The cases were very preterm infants born between 25 and 30 weeks of gestation and were clinically defined as SPTB in 2005–2008. In the Finnish cohorts, SPTB was defined as birth occurring after spontaneous onset of labor at <36 completed weeks + 1 day of gestation.
Umbilical cord blood, umbilical cord tissue, or saliva was obtained from the study subjects. Commercial kits were used to extract genomic DNA from blood, or Puregene Blood Core Kit and cord tissue using Qiagen’s Gentra Puregene Tissue Kit. Genome-wide SNP genotyping was performed with the Infinium HumanCoreExome BeadChip. In total, 18 placental samples were analyzed by immunohistochemistry.
The team reported that after replication testing in hundreds more babies born particularly prematurely and thousands of control infants, they were left with a single nucleotide polymorphism (SNP) in the SLIT2 gene that was significantly associated with spontaneous preterm birth, as well as suggestive associations for SNPs in other axon guidance genes. The team's follow-up gene expression, localization, and functional experiments indicated that SLIT2 and ROBO1, which encodes SLIT2's receptor protein, are expressed at higher-than-usual levels in certain parts of the placenta for infants experiencing spontaneous preterm birth.
The most significant association with spontaneous birth involved a SNP called rs116461311 in SLIT2, prompting a series of immunohistochemistry, qRT-PCR, and gene silencing experiments on placental samples or cells that the scientists used to decode SLIT2-ROBO1 interactions and their consequences for birth timing. The authors concluded that based on the currently available evidence they propose that activation of SLIT2-ROBO1 expression and signaling in [placental] trophoblast cells contributes to inflammatory and immune activation, which in turn leads to early labor and preterm birth. The study was published on June 13, 2019, in the journal PLOS Genetics.
Related Links:
Oulu University Hospital
Latest Molecular Diagnostics News
- Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
- Blood Test Could Help Detect Gallbladder Cancer Earlier
- New Blood Test Score Detects Hidden Alcohol-Related Liver Disease
- New Blood Test Predicts Who Will Most Likely Live Longer
- Genetic Test Predicts Radiation Therapy Risk for Prostate Cancer Patients
- Genetic Test Aids Early Detection and Improved Treatment for Cancers
- New Genome Sequencing Technique Measures Epstein-Barr Virus in Blood
- Blood Test Boosts Early Detection of Brain Cancer
- Molecular Monitoring Approach Helps Bladder Cancer Patients Avoid Surgery
- Genetic Tests to Speed Diagnosis of Lymphatic Disorders
- Changes In Lymphatic Vessels Can Aid Early Identification of Aggressive Oral Cancer
- New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids
- New CSF Liquid Biopsy Assay Reveals Genomic Insights for CNS Tumors
- AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy
- Group A Strep Molecular Test Delivers Definitive Results at POC in 15 Minutes
- Rapid Molecular Test Identifies Sepsis Patients Most Likely to Have Positive Blood Cultures
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Hidden Gut Viruses Linked to Colorectal Cancer Risk
Colorectal cancer (CRC) remains a leading cause of cancer mortality in many Western countries, and existing risk-stratification approaches leave substantial room for improvement. Although age, diet, and... Read more
Three-Test Panel Launched for Detection of Liver Fluke Infections
Parasitic liver fluke infections remain endemic in parts of Asia, where transmission commonly occurs through consumption of raw freshwater fish or aquatic plants. Chronic infection is a well-established... Read morePathology
view channel
Molecular Imaging to Reduce Need for Melanoma Biopsies
Melanoma is the deadliest form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Because early melanomas can closely resemble benign moles, clinicians often rely on visual... Read more
Urine Specimen Collection System Improves Diagnostic Accuracy and Efficiency
Urine testing is a critical, non-invasive diagnostic tool used to detect conditions such as pregnancy, urinary tract infections, metabolic disorders, cancer, and kidney disease. However, contaminated or... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







